Literature DB >> 8529805

Molecular responses of endothelial tissue to kinins.

R Busse1, I Fleming.   

Abstract

The endothelial response to kinin stimulation is the result of a series of complex intracellular reactions involving changes in the intracellular concentration of free calcium ([Ca2+]i) and intracellular pH, enhanced phosphorylation of several proteins via the activation of at least four distinct families of protein kinases, and activation of membrane ion transport systems. Some of the more recent developments in this field suggest that endothelial tyrosine kinases and tyrosine phosphatases as well as serine/threonine phosphatases are also activated in response to bradykinin. In addition, the finding that the mitogen-activated protein kinase (MAP kinase) pathway was tyrosine phosphorylated, and presumably activated, in endothelial cells after an increase in [Ca2+]i has wideranging implications for these cells. Indeed, MAP kinase recognizes many different substrates in the cell, including growth factor receptors, microtubule-associated proteins, specific serine-threonine protein kinases, phospholipase A2, and transcription factors. Further recent studies of interest have underscored the role of endothelium-derived hyperpolarizing factor in addition to nitric oxide and prostacyclin in the coronary vasculature. Indeed, this mediator, which seems to be an endothelium-derived, cytochrome P450-derived metabolite of arachidonic acid, would now appear to represent a substantial constitutive component of the vasodilator response to bradykinin.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8529805     DOI: 10.2337/diab.45.1.s8

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  10 in total

1.  Bradykinin attenuates the [Ca(2+)](i) response to angiotensin II of renal juxtamedullary efferent arterioles via an EDHF.

Authors:  J Marchetti; F Praddaude; R Rajerison; J L Ader; F Alhenc-Gelas
Journal:  Br J Pharmacol       Date:  2001-02       Impact factor: 8.739

2.  Calcium mobilization and protease-activated receptor cleavage after thrombin stimulation in motor neurons.

Authors:  I V Smirnova; S Vamos; T Wiegmann; B A Citron; P M Arnold; B W Festoff
Journal:  J Mol Neurosci       Date:  1998-02       Impact factor: 3.444

3.  Bradykinin activates the Janus-activated kinase/signal transducers and activators of transcription (JAK/STAT) pathway in vascular endothelial cells: localization of JAK/STAT signalling proteins in plasmalemmal caveolae.

Authors:  H Ju; V J Venema; H Liang; M B Harris; R Zou; R C Venema
Journal:  Biochem J       Date:  2000-10-01       Impact factor: 3.857

Review 4.  Diabetic Microvascular Disease: An Endocrine Society Scientific Statement.

Authors:  Eugene J Barrett; Zhenqi Liu; Mogher Khamaisi; George L King; Ronald Klein; Barbara E K Klein; Timothy M Hughes; Suzanne Craft; Barry I Freedman; Donald W Bowden; Aaron I Vinik; Carolina M Casellini
Journal:  J Clin Endocrinol Metab       Date:  2017-12-01       Impact factor: 5.958

Review 5.  ACE inhibition, endothelial function and coronary artery lesions. Role of kinins and nitric oxide.

Authors:  J V Mombouli
Journal:  Drugs       Date:  1997       Impact factor: 9.546

6.  Endothelial nitric oxide synthase interactions with G-protein-coupled receptors.

Authors:  M B Marrero; V J Venema; H Ju; H He; H Liang; R B Caldwell; R C Venema
Journal:  Biochem J       Date:  1999-10-15       Impact factor: 3.857

Review 7.  Plasma kallikrein-kinin system and diabetic retinopathy.

Authors:  Jia Liu; Edward P Feener
Journal:  Biol Chem       Date:  2013-03       Impact factor: 3.915

8.  Exercise-induced increase in interstitial bradykinin and adenosine concentrations in skeletal muscle and peritendinous tissue in humans.

Authors:  H Langberg; C Bjørn; R Boushel; Y Hellsten; M Kjaer
Journal:  J Physiol       Date:  2002-08-01       Impact factor: 5.182

Review 9.  Human tissue kallikrein in the treatment of acute ischemic stroke.

Authors:  Michelle Alexander-Curtis; Rick Pauls; Julie Chao; John J Volpi; Philip M Bath; Todd A Verdoorn
Journal:  Ther Adv Neurol Disord       Date:  2019-01-20       Impact factor: 6.570

10.  Preclinical characterization of recombinant human tissue kallikrein-1 as a novel treatment for type 2 diabetes mellitus.

Authors:  Tadeusz Kolodka; Matthew L Charles; Arvind Raghavan; Ilian A Radichev; Christina Amatya; Jacob Ellefson; Alexei Y Savinov; Abhijeet Nag; Mark S Williams; Mark S Robbins
Journal:  PLoS One       Date:  2014-08-06       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.